Loading
Tikva Allocell builds ready-made CAR-T cells from healthy donors' T cells that already fight the common Epstein-Barr virus, with an added shield to stop the patient's immune system rejecting them. Its first product targets a protein found on many solid tumours and was preparing for its first trial in 2026.
Tikva Allocell Pte Ltd is a late-preclinical Singapore company founded by Ivan Horak, with Baylor College of Medicine's Malcolm Brenner, Cliona Rooney and Helen Heslop as co-founders, and holds an exclusive licence to Baylor cell therapy technologies. Its platform starts from allogeneic Epstein-Barr virus-specific T cells (EBVSTs) from healthy donors, which carry low graft-versus-host risk without heavy gene editing, and arms them with an optimised SerpinB9 variant that inhibits granzyme B and caspases to resist host rejection and activation-induced cell death. It also lists an oncolytic virus strategy to modify the tumour microenvironment.
In July 2026 it closed a USD 8 million Series A led by Kantharos Capital to complete IND-enabling studies of its lead candidate TAVST01, which targets B7-H3, for clinical development in Singapore and the United States. The company names lung, breast, prostate, pancreatic, gastric, triple-negative breast and paediatric cancers as settings where B7-H3 is overexpressed.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by Kantharos Capital | 2026 | $8M | tikvaallocell.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares B7-H3, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares B7-H3, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares B7-H3, CAR-T cell therapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/